Compare CPF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPF | OMER |
|---|---|---|
| Founded | 1954 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 844.6M |
| IPO Year | 2011 | 2008 |
| Metric | CPF | OMER |
|---|---|---|
| Price | $35.81 | $18.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $43.00 | $27.50 |
| AVG Volume (30 Days) | 113.0K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | 45.18 | ★ 98.15 |
| EPS | ★ 1.58 | 0.77 |
| Revenue | ★ $51,817,000.00 | $29,868,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $3.52 | $73.58 |
| P/E Ratio | ★ $22.85 | $24.82 |
| Revenue Growth | ★ 33.81 | N/A |
| 52 Week Low | $27.40 | $4.06 |
| 52 Week High | $40.99 | $21.24 |
| Indicator | CPF | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 54.02 |
| Support Level | $35.09 | $18.00 |
| Resistance Level | $39.59 | $19.60 |
| Average True Range (ATR) | 0.74 | 0.84 |
| MACD | -0.15 | -0.16 |
| Stochastic Oscillator | 0.00 | 52.32 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.